HAPVIDA PARTICIPAÇÕES E INVESTIMENTOS

Hapvida reports a marked improvement in the loss ratio to 72.2% in Q1 2026 and an adjusted EBITDA of R$803m (margin 10.2%), indicating successful measures to control medical costs. Despite a decline of 44,500 insured individuals to 8.68 million, revenue remained stable at R$7,892m and adjusted net income rose to R$244m. Administrative expenses and legal disputes weighed on the cost structure, while free cash flow was robust at R$443m. Management is pursuing a five‑pillar turnaround focused on rational growth, network expansion, AI and capital discipline; analysts expect a return to profitability in 2026. » Más en de.investing.com

Hapvida reports an adjusted net profit decline of 64.9% in Q4 2025 to R$181m on a 5.9% rise in net revenue to R$7.915bn. Adjusted EBITDA fell 32.8% and the EBITDA margin dropped 520 basis points to 9.0%, while the cash‑MLR rose to 75.5%. On an organic basis the company lost 140,000 health plan members, mainly in the Southeast and South, and free cash flow was negative R$233m. Net debt increased to R$5.183bn and management announced a six‑pillar turnaround plan focused on customer retention, cost discipline and strengthening technology. » Más en de.investing.com

Hapvida reported net revenue of R$ 7,775 million in Q3 2025 (+6% y/y), but missed analyst expectations. The Cash Medical Loss Ratio rose to 75.2%, driven by higher hospital and emergency usage, which pushed adjusted EBITDA down to R$ 746 million (-17.6% q/q) and the EBITDA margin to 9.6%. Adjusted net income rose to R$ 338 million, while the stock fell sharply, losing about 33%. Management expects rate adjustments of around 10% by year-end and relies on network expansion and technology use to improve margins. » Más en de.investing.com